Prothrombotic alterations in plasma fibrin clot properties in thyroid disorders and their post-treatment modifications.

[1]  H. Büller,et al.  Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia , 2012, Thrombosis and Haemostasis.

[2]  V. Gerdes,et al.  The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors , 2012, Thrombosis and Haemostasis.

[3]  F. Tseng,et al.  Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults. , 2012, Journal of the American College of Cardiology.

[4]  R. Ajjan,et al.  Fibrin clot structure and fibrinolysis in hypothyroid individuals: the effects of normalising thyroid hormone levels , 2012, Journal of thrombosis and haemostasis : JTH.

[5]  M. Itoh,et al.  Relative levels of the inflammatory cytokine TNFα and the soluble CD40 ligand profile in serum correlate with the thyrotoxic activity of Graves' disease. , 2012, Thyroid : official journal of the American Thyroid Association.

[6]  V. Gerdes,et al.  Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals. , 2012, The Journal of clinical endocrinology and metabolism.

[7]  J. Zalewski,et al.  A history of early stent thrombosis is associated with prolonged clot lysis time , 2012, Thrombosis and Haemostasis.

[8]  E. Fliers,et al.  The incidence of venous thromboembolism in patients with overt hyperthyroidism , 2012, Thrombosis and Haemostasis.

[9]  Anetta Undas,et al.  Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[10]  A. Undas.  Acquired dysfibrinogenemia in atherosclerotic vascular disease. , 2011, Polskie Archiwum Medycyny Wewnetrznej.

[11]  G. Lippi,et al.  Hyperthyroidism and Venous Thrombosis: A Casual or Causal Association? A Systematic Literature Review , 2011, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[12]  J. Weisel,et al.  A novel missense mutation in the FGB g. 3354 T>A (p. Y41N), Fibrinogen Caracas VIII , 2011, Thrombosis and Haemostasis.

[13]  D. Ertuğrul,et al.  Mean platelet volume in patients with subclinical hypothyroidism , 2011, Platelets.

[14]  S. Guldıken,et al.  Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Antigen and Activity Assay in Patients With Primary Hypothyroidism , 2010, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[15]  F. Rosendaal,et al.  Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. , 2010, Blood.

[16]  A. Undas,et al.  Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis. , 2010, Thrombosis research.

[17]  W. Tracz,et al.  Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. , 2009, Blood.

[18]  C. Erem,et al.  Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism , 2009, Endocrine.

[19]  P. Stein,et al.  Venous Thromboembolism in Patients Hospitalized With Thyroid Dysfunction , 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[20]  E. Stępień,et al.  Altered Fibrin Clot Structure/Function in Patients With Cryptogenic Ischemic Stroke , 2009, Stroke.

[21]  V. Gerdes,et al.  Hypothyroidism and acquired von Willebrand’s syndrome: a systematic review , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  E. Stępień,et al.  Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. , 2008, Atherosclerosis.

[23]  A. Bianco,et al.  Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. , 2008, Endocrine reviews.

[24]  A. Comlekçi,et al.  The alteration of serum soluble CD40 ligand levels in overt and subclinical hypothyroidism. , 2007, Hormones.

[25]  H. Vierhapper,et al.  Altered platelet plug formation in hyperthyroidism and hypothyroidism. , 2007, The Journal of clinical endocrinology and metabolism.

[26]  H. Büller,et al.  Clinical review: Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. , 2007, The Journal of clinical endocrinology and metabolism.

[27]  A. Comlekçi,et al.  Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement. , 2007, Endocrine journal.

[28]  J. Weisel,et al.  Altered Fibrin Architecture Is Associated With Hypofibrinolysis and Premature Coronary Atherothrombosis , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[29]  A. Bianco,et al.  Deiodinases: implications of the local control of thyroid hormone action. , 2006, The Journal of clinical investigation.

[30]  A. Szczeklik,et al.  Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis , 2006, Journal of thrombosis and haemostasis : JTH.

[31]  P. Grant,et al.  The influence of type 2 diabetes on fibrin structure and function , 2005, Diabetologia.

[32]  Shen-Liang Chen,et al.  Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins. , 2004, Endocrinology.

[33]  P. Giral,et al.  Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. , 2001, The Journal of clinical endocrinology and metabolism.

[34]  Y. Ban,et al.  Plasma selectin levels in patients with Graves' disease. , 1996, Endocrine journal.

[35]  A. Undas,et al.  Altered fibrin clot properties in patients with premature peripheral artery disease. , 2012, Polskie Archiwum Medycyny Wewnetrznej.

[36]  N. Coplan,et al.  Embolic risk in atrial fibrillation that arises from hyperthyroidism: review of the medical literature. , 2011, Texas Heart Institute journal.

[37]  Ş. Çetinkalp,et al.  The effect of hormone replacement treatment on thrombin-activatable fibrinolysis inhibitor activity levels in patients with Hashimoto thyroiditis. , 2009, Internal medicine.